Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet ...Middle East

HONG KONG, March 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific antibody, ivonescimab, as a monotherapy...

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet )

Also on site :

• Nazi symbols prevalent in Ukrainian military – Le Monde
• The Solstice Shift: Your Zodiac Sign’s Summer Destiny
• Israel threatens to kill Iran’s supreme leader after missile strikes